BioSpace News Archive

The demand within the global hirsutism treatment market has been rising on account of advancements in the field of female healthcare and treatments.

The diabetic neuropathy market study by Fact.MR offers compelling insights into key growth drivers and restraints impacting the market through 2031.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per insights by Fact.MR, the global market for monopolar electrosurgery is anticipated to expand at a CAGR of 4.1% over the forecast period 2021-2031.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations, a Senior Manager of Clinical Trials, and a Senior Director of Biometrics.

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, announced the Company will provide a corporate update and report second quarter 2021 financial results on Monday, August 16.

23andMe Holding Co., a leading consumer genetics and research company, reported its financial results for the first quarter of its fiscal year 2022, which ended June 30, 2021.

Akero Therapeutics, Inc., a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis, reported second quarter financial results for the period ending June 30, 2021.

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the second quarter ended June 30, 2021 and provided upcoming company milestones.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2021.

Compass Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary antibody therapeutics announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer will participate in a fireside chat at the Citi 16th Annual Biopharma Conference.